Literature DB >> 15531111

The NR1 subunit of the glutamate/NMDA receptor in the superior temporal cortex in schizophrenia and affective disorders.

Sutisa Nudmamud-Thanoi1, Gavin P Reynolds.   

Abstract

The NMDA receptor has been implicated in the pathophysiology of several diseases including schizophrenia and affective disorders. We have investigated the NR1 subunit of the NMDA receptor in a well-defined series of psychiatric cases using radioligand binding and quantitative immunoblotting techniques. Saturable radioligand binding of [(3)H]L-689,560 to the glycine site on this subunit of the NMDA receptor was undertaken in superior temporal cortex of patients with schizophrenia, bipolar disorder, depression and matched control subjects. A tendency towards an increased receptor density was found in schizophrenia. A significant decrease in NMDA receptor density below control value was found in both bipolar and depressive disorders. The immunoblotting technique was used to identify NR1 protein in the same series of cases of which two bands were identified consistent with NR1 splice variants. A tendency to a decrease in the density of the NR1 upper band below control values was found in bipolar and depressed patients, but not schizophrenics. Consistent with this observation, the ratio between the upper and lower NR1-immunoreactive bands showed a significant decrease in bipolar disorder, although the ratio in depression did not reach significance. No significant difference was found in the NR1 lower band in any patient group compared with control. The finding of an increase NMDA receptor density in schizophrenia is consistent with the previous reports, with a possible compensatory response to glutamatergic deficits in superior temporal cortex in schizophrenia. The findings in affective disorders are interesting in respect of reports of cortical NMDA receptor deficits in suicide victims, although antidepressant drug treatment may contribute to these changes.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15531111     DOI: 10.1016/j.neulet.2004.09.035

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  36 in total

Review 1.  Clinical staging in the pathophysiology of psychotic and affective disorders: facilitation of prognosis and treatment.

Authors:  Trevor Archer; Richard M Kostrzewa; Tomas Palomo; Richard J Beninger
Journal:  Neurotox Res       Date:  2010-03-17       Impact factor: 3.911

Review 2.  A brief history of the development of antidepressant drugs: from monoamines to glutamate.

Authors:  Todd M Hillhouse; Joseph H Porter
Journal:  Exp Clin Psychopharmacol       Date:  2015-02       Impact factor: 3.157

3.  Elevated levels of the NR2C subunit of the NMDA receptor in the locus coeruleus in depression.

Authors:  Beata Karolewicz; Craig A Stockmeier; Gregory A Ordway
Journal:  Neuropsychopharmacology       Date:  2005-08       Impact factor: 7.853

4.  Transcription factor Sp4 regulates expression of nervous wreck 2 to control NMDAR1 levels and dendrite patterning.

Authors:  Xinxin Sun; Raquel Pinacho; Gregory Saia; Diana Punko; J Javier Meana; Belén Ramos; Grace Gill
Journal:  Dev Neurobiol       Date:  2014-07-22       Impact factor: 3.964

Review 5.  Mood-stabilizers target the brain arachidonic acid cascade.

Authors:  Jagadeesh S Rao; Stanley I Rapoport
Journal:  Curr Mol Pharmacol       Date:  2009-06       Impact factor: 3.339

Review 6.  [Immunological aspects of depressive disorders].

Authors:  N Müller; M J Schwarz
Journal:  Nervenarzt       Date:  2007-11       Impact factor: 1.214

7.  Elevated levels of NR2A and PSD-95 in the lateral amygdala in depression.

Authors:  Beata Karolewicz; Katalin Szebeni; Tempestt Gilmore; Dorota Maciag; Craig A Stockmeier; Gregory A Ordway
Journal:  Int J Neuropsychopharmacol       Date:  2008-06-23       Impact factor: 5.176

Review 8.  Ketamine and the next generation of antidepressants with a rapid onset of action.

Authors:  Rodrigo Machado-Vieira; Giacomo Salvadore; Nancy Diazgranados; Carlos A Zarate
Journal:  Pharmacol Ther       Date:  2009-05-03       Impact factor: 12.310

Review 9.  Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders.

Authors:  Gerard Sanacora; Carlos A Zarate; John H Krystal; Husseini K Manji
Journal:  Nat Rev Drug Discov       Date:  2008-05       Impact factor: 84.694

10.  Pharmacology and therapeutic potential of sigma(1) receptor ligands.

Authors:  E J Cobos; J M Entrena; F R Nieto; C M Cendán; E Del Pozo
Journal:  Curr Neuropharmacol       Date:  2008-12       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.